You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

266 Results
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Lymphoblastic (ALL), 
Leukemia - Chronic Lymphocytic (CLL), 
Leukemia - Hairy Cell, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Curative, Palliative
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Adjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Neoadjuvant
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Therapy for Resectable Non-Small Cell Lung Cancer
Jul 2025
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Jul 2025
Drug
Other Name(s): Welireg®
Jul 2025
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®, Filra™
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Leukemia - Chronic Myeloid (CML)
Intent: Palliative
Funding:
Exceptional Access Program
    asciminib - For the treatment of Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, based on criteria
Jul 2025

Pages